Signal2026-06-10
ClinicalTrials.gov

[PHASE2] Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer

Part of

Molecular Profiling In Endocrine Neoplasms

Open primary sourceSee the whole picture